Chronic Pain - Pipeline Review - H2 2014





 
Date: July 2014 | Report Format: PDF

 
Description

Global Markets Direct’s, ‘Chronic Pain - Pipeline Review, H2 2014’, provides an overview of the Chronic Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chronic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
 

 

 

Reasons to Buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 

 

 

 
 

 

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Chronic Pain Overview 11

Therapeutics Development 12

Pipeline Products for Chronic Pain - Overview 12

Pipeline Products for Chronic Pain - Comparative Analysis 13

Chronic Pain - Therapeutics under Development by Companies 14

Chronic Pain - Therapeutics under Investigation by Universities/Institutes 20

Chronic Pain - Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Unknown Stage Products 25

Chronic Pain - Products under Development by Companies 26

Chronic Pain - Products under Investigation by Universities/Institutes 34

Chronic Pain - Companies Involved in Therapeutics Development 35

DURECT Corporation 35

Johnson & Johnson 36

Allergan, Inc. 37

UMeWorld Limited 38

AstraZeneca PLC 39

Eli Lilly and Company 40

Nektar Therapeutics 41

Daiichi Sankyo Company, Limited 42

Merck & Co., Inc. 43

Santen Pharmaceutical Co., Ltd. 44

Egalet Corporation 45

Daewoong Pharmaceutical Co., Ltd. 46

Laboratorios Del Dr. Esteve S.A. 47

Glenmark Pharmaceuticals Ltd. 48

Nippon Shinyaku Co., Ltd. 49

Orion Corporation 50

Pain Therapeutics, Inc. 51

Pfizer Inc. 52

Purdue Pharma L.P. 53

Teva Pharmaceutical Industries Limited 54

Collegium Pharmaceutical, Inc. 55

Bionomics Limited 56

Acadia Pharmaceuticals Inc. 57

Pozen, Inc. 58

Mertiva AB 59

INSYS Therapeutics, Inc. 60

Chromocell Corporation 61

BCN Peptides, S.A. 62

Phosphagenics Limited 63

Pharmaleads 64

Grunenthal GmbH 65

CoLucid Pharmaceuticals, Inc. 66

Trevena, Inc. 67

Syntrix Biosystems, Inc. 68

Kineta, Inc. 69

Rottapharm SpA 70

QRxPharma Limited 71

Cara Therapeutics, Inc. 72

arGEN-X BV 73

Moberg Pharma AB 74

Janssen Research & Development, LLC 75

Dompe Farmaceutici S.p.A. 76

Endo Pharmaceuticals Inc. 77

Lohocla Research Corporation 78

Relmada Therapeutics, Inc. 79

Afferent Pharmaceuticals, Inc. 80

Convergence Pharmaceuticals Ltd. 81

Adynxx, Inc. 82

Kareus Therapeutics, SA 83

Astraea Therapeutics, LLC 84

Signature Therapeutics, Inc 85

AnaBios Corporation 86

CFR Pharmaceuticals SA 87

Recro Pharma, Inc. 88

Creabilis SA 89

Neura Therapeutik, LLC 90

AbbVie Inc. 91

Nanomerics Ltd 92

ChironWells GmbH 93

Akron Molecules AG 94

GlobalAcorn 95

Chronic Pain - Therapeutics Assessment 96

Assessment by Monotherapy Products 96

Assessment by Combination Products 97

Assessment by Target 98

Assessment by Mechanism of Action 103

Assessment by Route of Administration 108

Assessment by Molecule Type 110

Drug Profiles 112

tramadol hydrochloride SR - Drug Profile 112

(oxycodone hydrochloride + naloxone hydrochloride) ER - Drug Profile 113

hydrocodone bitartrate ER - Drug Profile 115

celecoxib - Drug Profile 116

oxycodone ER - Drug Profile 118

hydrocodone bitartrate ER - Drug Profile 120

tapentadol hydrochloride - Drug Profile 122

duloxetine hydrochloride DR - Drug Profile 123

oxycodone hydrochloride ER - Drug Profile 125

buprenorphine hydrochloride - Drug Profile 126

tapentadol hydrochloride ER - Drug Profile 128

(oxycodone hydrochloride + naltrexone hydrochloride) ER - Drug Profile 131

PRC-062 - Drug Profile 133

sufentanil - Drug Profile 134

(morphine + oxycodone) CR - Drug Profile 136

AGN-XX/YY - Drug Profile 137

cebranopadol - Drug Profile 138

morphine sulfate ER - Drug Profile 140

onabotulinumtoxinA - Drug Profile 141

NKTR-181 - Drug Profile 143

dexmedetomidine hydrochloride - Drug Profile 145

mirogabalin - Drug Profile 147

levorphanol tartrate ER - Drug Profile 148

dexmedetomidine - Drug Profile 149

(celecoxib + tramadol hydrochloride) - Drug Profile 151

E-52862 - Drug Profile 153

AYX-1 - Drug Profile 154

V-116517 - Drug Profile 155

bupivacaine hydrochloride - Drug Profile 156

oxycodone - Drug Profile 158

PTI-202 - Drug Profile 160

hydromorphone - Drug Profile 162

hydrocodone bitartrate - Drug Profile 163

PL-37 - Drug Profile 164

PTI-721 - Drug Profile 165

PA-65020 - Drug Profile 166

CR-845 - Drug Profile 167

oxycodone ER - Drug Profile 169

PF-05089771 - Drug Profile 170

PF-329 - Drug Profile 172

PF-06273340 - Drug Profile 174

HS-731 - Drug Profile 175

DD-04107 - Drug Profile 176

TRV-734 - Drug Profile 177

PF-06372865 - Drug Profile 178

Small Molecule to Agonize mGlu2/3 for Chronic Pain - Drug Profile 179

DS-1971 - Drug Profile 180

AF-220 - Drug Profile 181

AF-221 - Drug Profile 182

oxymorphone - Drug Profile 183

GBR-900 - Drug Profile 184

DWJ-208 - Drug Profile 185

CT-340 - Drug Profile 186

RQ-00000008 - Drug Profile 187

CR-701 - Drug Profile 188

buprenorphine hydrochloride ER - Drug Profile 189

Z-212 - Drug Profile 190

ARX-8203 - Drug Profile 191

Small Molecule to Inhibit Cav2.2 Channel for Chronic Pain - Drug Profile 193

CNV-3000223 - Drug Profile 194

PFR-03088 - Drug Profile 195

PF-614 - Drug Profile 196

PFR-06158 - Drug Profile 197

PF-6129 - Drug Profile 198

Conjugated Stigmine Program - Drug Profile 199

Small Molecule Agonizing ER-Beta for Neurology and Pain - Drug Profile 200

Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile 201

Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile 202

FY-101C - Drug Profile 203

Small Molecule To Inhibit GPR-84 For Chronic Pain - Drug Profile 204

grapiprant - Drug Profile 205

NE2 Endomorphin - Drug Profile 207

HS-731 - Drug Profile 208

Small Molecules to Block Nav 1.7 for Pain - Drug Profile 209

Small Molecule to Inhibit P2Y14 for Chronic Pain - Drug Profile 210

Prostatic Acid Phosphatase - Drug Profile 211

Small Molecule for Neuropathic Pain and Inflammatory Pain - Drug Profile 212

NL-001 - Drug Profile 213

PFR-06177 - Drug Profile 214

PFR-03318 - Drug Profile 215

U-2902 - Drug Profile 216

CNV-3000164 - Drug Profile 217

A-836339 - Drug Profile 218

NL-002 - Drug Profile 219

fluticasone propionate - Drug Profile 220

CRB-0089 - Drug Profile 221

Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile 222

NET-END - Drug Profile 223

Drugs for Chronic Pelvic Pain - Drug Profile 224

UMB-425 - Drug Profile 225

Peptide to Block Calcium Channel for CNS Disorders - Drug Profile 226

PFR-03321 - Drug Profile 227

Small Molecules to Inhibit TRPA1 and TRPV1 for CNS - Drug Profile 228

Omnitram - Drug Profile 230

GA-8SMOL-PAIN - Drug Profile 231

Small Molecules to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 232

SA-14867 - Drug Profile 233

TROX-1 - Drug Profile 234

BBI-11008 - Drug Profile 235

NM-0127 - Drug Profile 236

Small Molecules to Activate NOP for Pain - Drug Profile 237

buprenorphine hydrochloride - Drug Profile 238

Small Molecules to Inhibit Cav2.2 Channel for Chronic Pain - Drug Profile 239

Small Molecules to Antagonize P2X3 for Chronic Pain - Drug Profile 240

DF-2593A - Drug Profile 241

Protein to Antagonize p75NTR for Chronic Pain - Drug Profile 242

Small Molecule for Central Nervous System - Drug Profile 243

Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 245

Kindolor - Drug Profile 246

CRB-0022 - Drug Profile 248

PFR-03325 - Drug Profile 249

Small Molecule To Inhibit Voltage-Gated Sodium Channel Type IX Alpha For Pain - Drug Profile 250

Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 251

Small Molecules to Antagonize Tyrosine Kinase Receptor A for Chronic Pain - Drug Profile 252

Small Molecules to Inhibit NMDA Receptor and CHRNA7 for CNS - Drug Profile 253

AKR-201 - Drug Profile 254

Monoclonal Antibodies Targeting Nav1.7 for Chronic Pain - Drug Profile 255

PFR-03323 - Drug Profile 256

Small Molecule to Antagonize TRPA1 for Chronic Pain - Drug Profile 257

Peptides for Chronic Pain - Drug Profile 258

KY-1017 - Drug Profile 259

hydrocodone bitartrate ER - Drug Profile 260

Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 261

GRT-6006 - Drug Profile 262

VLNX-4975 - Drug Profile 263

Monoclonal Antibodies for Chronic Pain - Drug Profile 264

Chronic Pain - Recent Pipeline Updates 265

Chronic Pain - Dormant Projects 296

Chronic Pain - Discontinued Products 302

Chronic Pain - Product Development Milestones 303

Featured News & Press Releases 303

Appendix 310

Methodology 310

Coverage 310

Secondary Research 310

Primary Research 310

Expert Panel Validation 310

Contact Us 311

Disclaimer 311